Eckert & Ziegler increases earnings by 17%

Berlin, (PresseBox) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a specialist for cancer radiation and radiometric systems, posted a surplus after taxes and minority distributions of 760,000 EUR or 0.24 EUR per share, representing an increase of 17% over last year's figure of 650,000 EUR (0.21 EUR per share). Overall group sales rose by 15% to 13 million EUR.

As in previous quarters and in spite of a recently unfavorable US dollar exchange rate development, the most profitable area was the Nuclear Medicine and Imaging segment, which contributed 560,000 EUR to the total surplus (last year: 360,000 EUR). The Therapy segment raised its earnings from 160,000 to 350,000 EUR, while the Radiopharmaceuticals segment, which is currently under development, posted a loss of 160,000 EUR. Sales in the Therapy segment represented an especially strong growth factor, benefiting from a large-scale contract for tumor radiation systems and rising volumes of prostate implants.

For the current business year, the Board anticipates sales of around 55 million EUR and profits of 2.8 million EUR (0.90 EUR per share).

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.